What is Porphyria?

Porphyria is a group of liver disorders characterised by the accumulation of porphyrins, which can adversely affect the skin or nervous system. The types of porphyria that affect the nervous system and have a rapid onset with short duration are known as acute porphyrias. 

Symptoms include severe abdominal pain, chest pain, vomiting, confusion, constipation, fever, high blood pressure, and rapid heart rate. Attacks typically present with pain and can last for several days. Complications may include paralysis, low sodium levels, and seizures. 

Alcohol, smoking, hormonal changes, fasting, stress, or certain medications can trigger symptoms. If the skin is affected, exposure to sunlight can cause blisters or itching. Porphyria is a genetic disorder that can negatively impact quality of life over the long term and requires treatment. 

Source:

1. Cavestro GM, Frulloni L, Cerati E, Ribeiro LA, Corrente V, Sianesi M, Franze A, Di Mario F. Progressive familial intrahepatic cholestasis. Acta Biomed. 2002; 73: 53-56. 
2. Davit-Spraul, A., Gonzales, E., Baussan, C., & Jacquemin, E. (2009). Progressive familial intrahepatic cholestasis. Orphanet journal of rare diseases, 4(1), 1-12. 
3. Jacquemin E. Progressive familial intrahepatic cholestasis. Genetic basis and treatment. Clin LiverDis 2000; 4: 753-63. 
4. Felzen, A., & Verkade, H. J. (2021). The spectrum of Progressive Familial Intrahepatic Cholestasis diseases: Update on pathophysiology and emerging treatments. European journal of medical genetics, 64(11), 104317. 
5. Mehl, A., Bohorquez, H., Serrano, M.S., Galliano, G., Reichman, T.W., 2016. Liver transplantation and the management of progressive familial intrahepatic cholestasis in children. World J. Transplant. 6 (2), 278–290. 
6. Gomez-Ospina, N., Potter, C.J., Xiao, R., Manickam, K., Kim, M.S., Kim, K.H., et al., 2016. Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis. Nat. Commun. 7, 10713. 
7. Gonzales, E., Taylor, S.A., Davit-Spraul, A., Thebaut, A., Thomassin, N., Guettier, C., et al., 2017. MYO5B mutations cause cholestasis with normal serum gamma-glutamyl transferase activity in children without microvillous inclusion disease. Hepatology 65 (1), 164–173. 
8. Maddirevula, S., Alhebbi, H., Alqahtani, A., Algoufi, T., Alsaif, H.S., Ibrahim, N., et al., 2019. Identification of novel loci for pediatric cholestatic liver disease defined by KIF12, PPM1F, USP53, LSR, and WDR83OS pathogenic variants. Genet. Med. 21 (5), 1164–1172. 
9. Rebhandl W, Felberbauer FX, Huber WD, et al. Progressive familial intrahepatic cholestasis (Byler disease): current genetics and therapy. Klin Padiatr 2000; 212: 64-70.